A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes

Trial Profile

A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2010

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation; Pharmion Corporation
  • Most Recent Events

    • 02 Mar 2009 Results reported in the Journal of Clinical Oncology.
    • 23 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov. The actual completion date was September 2008.
    • 22 Sep 2008 Celgene Corporations added as an Affiliate and Sponsor, reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top